Our findings provide a mechanistic basis for the transcriptional silencing of the FXN gene in Friedreich ataxia that is consistent with this response to HDAC inhibitors, and elucidate a rational basis for their action. The gene discussed is FXN; the disease is Friedreich ataxia.